https://www.news-medical.net/news/20090916/Optimers-North-American-phase-3-Fidaxomicin-study-results-presented-at-the-49th-ICAAC.aspx
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of...
north americanstudy resultsoptimerphasefidaxomicin
https://www.prnewswire.com/news-releases/optimer-pharmaceuticals-and-astrazeneca-collaborate-to-commercialize-fidaxomicin-for-clostridium-difficile-infection-in-latin-america-181819621.html
/PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca to commercialize...
optimer pharmaceuticalsastrazenecacollaboratecommercializefidaxomicin